Table 3. Risk of developing MetS based on corrected serum calcium tertile at baseline.
| Variable | Corrected serum calcium tertile, mg/dL | P for trenda | Continuous variables HR (95% CI) | ||
|---|---|---|---|---|---|
| Tertile 1 (<8.70) |
Tertile 2 (8.70–8.94) |
Tertile 3 (>8.94) |
|||
| Number | 4,174 | 4,334 | 4,198 | 0.482b | |
| Incident cases, n (%) | 1,164 (27.9) | 1,194 (27.5) | 1,090 (26.0) | ||
| Person-years of follow-up | 18,925 | 18,974 | 17,320 | ||
| Incident cases of MetS/1,000 person-year | 61.5 | 62.9 | 62.9 | ||
| Adjusted HR (95% CI)a | |||||
| Crude model | 1 (reference) | 1.02 (0.94–1.11) | 1.02 (0.94–1.11) | 0.849 | 1.05 (0.93–1.19) |
| Model 1 | 1 (reference) | 1.01 (0.93–1.10) | 1.02 (0.94–1.11) | 0.915 | 1.06 (0.94–1.20) |
| Model 2 | 1 (reference) | 0.91 (0.84–0.99) | 0.85 (0.78–0.92) | 0.001 | 0.80 (0.71–0.91) |
Model 1: adjusted for age and sex; Model 2: adjusted for model 1+systolic blood pressure, diastolic blood pressure, triglyceride, high density lipoprotein, fasting plasma glucose, smoking status, and conditions under medical treatment, including hypertension, diabetes, and hypercholesterolemia.
MetS, metabolic syndrome; HR, hazard ratio; CI, confidence interval.
aCox proportional hazard model, bChi-square test for linear by linear association.